Routine thyroid ultrasound screening may not be necessary for all acromegaly patients, according to new research that found detecting more thyroid nodules didn't translate into catching more dangerous cancers. Instead, doctors should use a risk-based approach similar to general population guidelines, experts say. This finding could spare thousands of patients from unnecessary imaging and follow-up procedures. What Did the Study Actually Find? Researchers analyzed data from 1,830 acromegaly patients, with 1,075 undergoing thyroid ultrasound at their center. The results were striking: 71.2% of acromegaly patients had at least one thyroid nodule at baseline, compared to just 43.7% in a control group of 17,839 people without acromegaly. The nodules in acromegaly patients were also slightly larger, with a median size of 0.7 centimeters versus 0.5 centimeters in controls. Despite this higher burden of nodular disease, thyroid cancer remained uncommon. Over an average follow-up of 3.9 years, only 25 new thyroid cancers (3.3%) were detected, and these cancers predominantly arose from nodules already classified as higher-risk on imaging. Notably, no cancers developed in patients who had no baseline nodules during more than 1,183 person-years of observation. Why Should Acromegaly Patients Care About This Finding? Acromegaly is a rare hormonal disorder caused by excessive growth hormone production, often from a pituitary tumor. Because growth hormone can affect multiple body systems, doctors have routinely screened acromegaly patients for thyroid problems. However, this new evidence suggests that blanket screening may be creating more problems than it solves. When doctors find thyroid nodules in 71% of patients, many of those people undergo repeat imaging, biopsies, and specialist consultations, even though most nodules never become dangerous. The study found that 71.4% of nodules remained stable or actually shrank over time, while only 7.5% increased in size. This means the vast majority of detected nodules cause unnecessary anxiety and medical appointments without any health benefit. How Should Doctors Approach Thyroid Screening in Acromegaly? - Risk Stratification First: Use imaging classification systems like the American College of Radiology Thyroid Imaging Reporting and Data System to identify which nodules actually need follow-up. Nodules classified as TR4 or TR5 (moderately or highly suspicious) had cancer rates of 5.5% and 15.9% respectively, while lower-risk categories rarely developed cancer. - Baseline Ultrasound Not Routine: Rather than screening all acromegaly patients at diagnosis, doctors should reserve ultrasound for patients with specific risk factors or symptoms. This approach aligns with recommendations for the general population. - Biochemical Markers Have Limited Value: Growth hormone and insulin-like growth factor 1 levels were not associated with thyroid cancer risk, meaning controlling these hormones doesn't predict who will develop thyroid cancer. The study authors concluded that the evidence doesn't support routine baseline thyroid ultrasound for all acromegaly patients at diagnosis. Instead, they stated that "surveillance of detected thyroid nodules in acromegaly may follow standard recommendations in the general population". What About Patients Already Being Screened? For acromegaly patients who have already had thyroid ultrasounds, the good news is that most detected cancers were low-risk papillary microcarcinomas, and treatment outcomes were generally excellent or indeterminate. Serious complications were infrequent, with no reported disease-related deaths in the study population. This suggests that even if cancers are found through screening, they tend to be slow-growing and manageable. The research included 339 patients with repeat imaging over an average of 2.8 years, providing solid evidence about how nodules behave over time. Older age at acromegaly diagnosis and longer follow-up duration were associated with higher thyroid cancer risk, but these factors alone don't justify screening everyone. This shift toward risk-based screening represents a broader movement in medicine away from one-size-fits-all screening toward personalized approaches that consider individual risk factors. For acromegaly patients, it means fewer unnecessary ultrasounds, less anxiety about incidental findings, and more focused medical care.
